Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma

Solomon N. Levin,Michael D. Tomasini,James Knox,Mahsa Shirani,Bassem Shebl,David Requena,Jackson Clark,Søren Heissel,Hanan Alwaseem,Rodrigo Surjan,Ron Lahasky,Henrik Molina,Michael S. Torbenson,Barbara Lyons,Rachael D. Migler,Philip Coffino,Sanford M. Simon
DOI: https://doi.org/10.1126/sciadv.adg7038
IF: 13.6
2023-06-23
Science Advances
Abstract:Fibrolamellar hepatocellular carcinoma (FLC) is a usually lethal primary liver cancer driven by a somatic dysregulation of protein kinase A. We show that the proteome of FLC tumors is distinct from that of adjacent nontransformed tissue. These changes can account for some of the cell biological and pathological alterations in FLC cells, including their drug sensitivity and glycolysis. Hyperammonemic encephalopathy is a recurrent problem in these patients, and established treatments based on the assumption of liver failure are unsuccessful. We show that many of the enzymes that produce ammonia are increased and those that consume ammonia are decreased. We also demonstrate that the metabolites of these enzymes change as expected. Thus, hyperammonemic encephalopathy in FLC may require alternative therapeutics.
multidisciplinary sciences
What problem does this paper attempt to address?